Clinical trials: Antibody Mediated Rejection
Renal Transplant Rejection, Pediatric Kidney Disease
VIRTUUS Children's Study
The objective of the VIRTUUS Children's Study is to adapt identified and validated adult noninvasive diagnostic and prognostic biomarkers for the characterization of allograft status in pediatric recipients of kidney allografts.
- Conditions
- Renal Transplant Rejection, Pediatric Kidney Disease, End Stage Renal Disease, Nephropathy
- Trial name
- VIRTUUS (NCT03719339)
- Where
- 13 sites in United States, Canada
- Volunteers
- 445 people
- Sponsor
- Children's Hospital of Philadelphia
Antibody-mediated Rejection, Autoimmune Reaction Mediated by Immune Complex
Elimination of Cardiac and Inflammatory Biomarkers and Adipokines by Therapeutic Plasma Exchange
Therapeutic plasma exchange (TPE) is an established treatment modality for the acute removal of pathophysiological relevant mediators in various diseases.
- Trial name
- NCT02533596
- Where
- Germany
- Volunteers
- 21 people
- Sponsor
- Hannover Medical School
Transplant Failure, Heart Transplant Rejection
MuLtimodality EvaluatiOn of aNtibody mEdiated Damage in Heart Transplantation (LEONE-HT)
Cross-sectional evaluation of antibody mediated injury in heart transplantation patients through a multimodal approach: electron microscopy, optic microscopy, immunohistochemistry techniques, transthoracic echocardiography…
- Conditions
- Transplant Failure, Heart Transplant Rejection, Antibody-mediated Rejection
- Trial name
- LEONE-HT (NCT05184426)
- Testing
- Echocardiogram, Cardiac magnetic resonance, Coronary angiography
- Where
- 3 sites in Spain
- Volunteers
- 90 people
- Sponsor
- Juan Francisco Delgado Jimenez
Lung Transplant Rejection, Antibody-mediated Rejection
Lung Transplant Plasmapheresis/Belatacept/Carfilzomib for Antibody Mediated Rejection and Desensitization
Antibody mediated rejection (AMR) post transplant contributes to poor long term outcomes after lung transplantation. Additionally, high antibodies detected pre transplant in candidates limit donor availability for lung…
- Trial name
- NCT03805178
- Testing
- Belatacept, Carfilzomib
- Sponsor
- Duke University
Transplant; Complication, Rejection
Mechanistic Evaluation of Treatments for Acute Antibody-Mediated Rejection of the Kidney Transplant
The best treatment for kidney failure is a kidney transplant, but a transplanted kidney only works for about 10 to 15 years on average.
- Trial name
- MOT-AMR (NCT04496037)
- Testing
- Rituximab
- Volunteers
- 170 people
- Sponsor
- Imperial College London
Subclinical Acute Antibody-mediated Rejection in Kidney Transplantation
Eculizumab Therapy for Subclinical Antibody-mediated Rejection in Kidney Transplantation
Advances in renal transplantation have increased life-expectancy in patients with end-stage kidney disease. Conventional immunosuppressive drugs prevent efficiently early allograft losses due to T-cell mediated rejection.
- Trial name
- TAMARCIN (NCT02113891)
- Testing
- Eculizumab
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Antibody-mediated Rejection
Subclass of Donor-specific Antibody as a Risk Factor of Antibody Mediated Rejection in Renal Transplantation
Antibody-mediated rejection is now recognized as the first cause of long-term kidney transplant loss. This type of rejection is mediated by the presence of graft-specific antibodies, usually directed against HLA (Human Leukocyte…
- Trial name
- COR-HUM (NCT04026087)
- Where
- France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Montpellier
Antibody Mediated Rejection of Lung Transplant
A Phase 1 Clinical Trial of Siltuximab for the Treatment of Antibody-Mediated Rejection After Lung Transplantation
Antibody-mediated rejection after lung transplantation commonly results in allograft failure and death in spite of current therapeutic regimens.
- Trial name
- Siltux-AMR (NCT06990711)
- Testing
- Siltuximab
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Washington University School of Medicine
Antibody Mediated Rejection
Safety & Efficacy of Eculizumab to Prevent AMR in Living Donor Kidney Transplant Recipients Requiring Desensitization
The purpose of this trial was to determine the safety and efficacy of eculizumab in the prevention of antibody-mediated rejection (AMR) in sensitized recipients of a living donor kidney transplant requiring desensitization…
- Trial name
- NCT01399593
- Testing
- Eculizumab
- Where
- 41 sites in United States, Australia and 8 more
- Volunteers
- 102 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Renal Transplantation
Endothelial Microparticules and Antibody Mediated Rejection and Kidney Transplantation: Biomarker of Antibody-mediated Rejection in Kidney Transplantation
Context and rationale: Antibody-mediated rejection is the leading cause of long-term renal graft loss. It's due to the production by the recipient of antibodies directed against antigens (belonging or not to the HLA system)…
- Trial name
- MICROMARK RJ (NCT03098238)
- Testing
- Biological sample
- Where
- France
- Volunteers
- 249 people, healthy volunteers welcome
- Sponsor
- University Hospital, Montpellier
Kidney Transplant, Rejection of Renal Transplant
Development and Validation of HistoMX, a Gene-Expression Platform for Molecular Interpretation of Kidney Allograft Biopsies
This retrospective multicentre observational study developed and validated HistoMX, an automated gene-expression-based platform for multidimensional molecular interpretation of kidney allograft biopsies.
- Conditions
- Kidney Transplant, Rejection of Renal Transplant, Antibody Mediated Rejection, BK Virus Nephropathy
- Trial name
- HistoMX (NCT07700563)
- Volunteers
- 2,410 people
- Sponsor
- Paris Translational Research Center for Organ Transplantation
Lung Transplant Recipient, Donor Specific Antibodies
DSA Intragraft in Lung Transplantation: Diagnostic and Prognostic Value in Antibody Mediated Rejection
The diagnosis of AMR in lung transplant recipients is difficult and often comes too late, because of lack of standardized definition.
- Conditions
- Lung Transplant Recipient, Donor Specific Antibodies, Antibody Mediated Rejection
- Trial name
- NCT03702257
- Testing
- bronchoscopy.
- Where
- 5 sites in France
- Volunteers
- 80 people
- Sponsor
- University Hospital, Strasbourg, France
Kidney Transplant
Adipose-derived MSC to Treat Rejection in Kidney Transplant Recipients
This research study is being done to learn if an experimental treatment of infusing allogeneic adipose-derived mesenchymal stromal cells (allo-A-MSC ) directly into the renal artery is safe and can help reduce inflammation in the…
- Trial name
- NCT05456243
- Testing
- Low dose adipose tissue derived mesenchymal stromal cells (A-MSC), High dose adipose tissue derived mesenchymal stromal cells (A-MSC)
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Mayo Clinic
Kidney Failure, Chronic, End-Stage Renal Disease
Clazakizumab in Highly-HLA Sensitized Patients Awaiting Renal Transplant
Patients who have had a previous allograft failure represent a major problem for transplant centers as they are highly-human leukocyte antigen (HLA) sensitized and unlikely to receive another transplant without significant…
- Conditions
- Kidney Failure, Chronic, End-Stage Renal Disease, Transplant Glomerulopathy, Transplant;Failure,Kidney
- Trial name
- NCT03380962
- Testing
- Clazakizumab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Stanley Jordan, MD
Heart Transplantation, Rejection Heart Transplant
CARdiac Imaging and BIomarkers in the Diagnosis of Antibody Mediated Rejection in Heart Transplantation
The goal of this observational study is to systematically assess the presence and distribution of CMR-defined inflammation and fibrosis in clinically stable HT recipients with DSA detected during active screening for AMR…
- Conditions
- Heart Transplantation, Rejection Heart Transplant, HLA Antigens
- Trial name
- CARIBIAM (NCT06774365)
- Where
- 4 sites in Italy
- Volunteers
- 683 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Antibody-mediated Rejection
Felzartamab in Late Antibody-Mediated Rejection
This prospective trial will assess the safety, tolerability, pharmacokinetics, immunogenicity, pharmacodynamics and efficacy of the fully human CD38 monoclonal antibody felzartamab in kidney transplant recipients with late active…
- Trial name
- NCT05021484
- Testing
- Felzartamab
- Where
- 2 sites in Austria, Germany
- Volunteers
- 22 people
- Sponsor
- Farsad Eskandary
Antibody-mediated Rejection
Comparison Between Bortezomib and Rituximab Plus Plasmapheresis in AMR
Chronic-active antibody-mediated rejection (cAMR) due to de novo or pre-formed donor specific antibody (DSA) is currently considered the main cause of long-term allograft losses.Based on the aim of reducing or eliminating DSA…
- Trial name
- NCT03737136
- Testing
- Bortezomib
- Where
- Iran
- Volunteers
- 20 people
- Sponsor
- Shahid Beheshti University of Medical Sciences
Acute Antibody-Mediated Rejection (AMR)
A Multicenter Study to Evaluate the Efficacy and Safety of Cinryze® for the Treatment of Acute Antibody-mediated Rejection in Participants With Kidney Transplant
The main purpose of the study is to evaluate the efficacy of CINRYZE administered with plasmapheresis, plasma exchange, or immune adsorption treatments and sucrose-free immunoglobulin (IVIg) for the treatment of acute…
- Trial name
- NCT02547220
- Testing
- Cinryze®
- Where
- 47 sites in United States, Canada and 4 more
- Volunteers
- 39 people
- Sponsor
- Shire
Graft Rejection, Kidney Transplantation
TRAnscriptional Profile of Peripheral Blood Cells in Patient With Chronic Kidney and Lung Rejection: Correlation With Response to Extracorporeal Photo-aphereSiS
With this project, the research team aims to identify the molecular pathways associated with the response to extracorporeal photonchemioapheresis (ECP) in kidney or lung transplant patients suffering from chronic rejection, by…
- Conditions
- Graft Rejection, Kidney Transplantation, Lung Transplantation, Antibody-Mediated Rejection
- Trial name
- TRACKLESS (NCT07316829)
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
Antibody-mediated Rejection, NMO Spectrum Disorder
Biorepository and Registry for Plasma Exchange Patients
Patients who have immune mediated diseases commonly undergo plasma exchange (PLEX) procedures to remove pathological substances, typically believed to be antibodies.
- Conditions
- Antibody-mediated Rejection, NMO Spectrum Disorder, TTP, CIDP
- Trial name
- NCT05004493
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Charles M Knudson